GSK could double its long-serving CEO Emma Walmsley’s pay packet to £21.6 million ($27.2 million) after admitting its boss's ...

GSK CEO Emma Walmsley’s $13 million salary is predicated on picking the right people to steer cutting-edge drug development for the world’s most challenging diseases. During her eight years at ...

This month marks the start of a new era for GlaxoSmithKline, with Emma Walmsley ... hit the market this year, GSK said earnings will be flat, or decrease slightly. Walmsley, who used to head ...

CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh Furlong and Ruth David of Bloomberg reports. The U.S.

GlaxoSmithKline’s new CEO Emma Walmsley is set to outline ... MaxiNutrition sports nutrition brand. Bought by GSK under the leadership of Walmsley’s predecessor, Sir Andrew Witty, the business ...

GSK is betting on AI to boost innovation for ... but a balanced approach toward regulation is important, CEO Emma Walmsley says. Speaking at the CEO Times Summit in London, Walmsley highlights ...

Given the current volatility and potential risks, I recommend holding off on buying GSK stock in 2025 ... full year 2024 earnings - as CEO Dame Emma Walmsley put it on the Q4 2024 earnings ...

Following the divestment of the consumer group in 2022, GSK lowered the overall dividend to a level that is likely more appropriate for the earnings. Emma Walmsley succeeded Andrew Witty as CEO in ...

GSK is studying a group of more than a million older adults in the UK to see if its shingles vaccine lowers the risk of dementia. The British drugs group, led by boss Emma Walmsley, is using the ...